Aspectos destacados del Taller de Laboratorio de Anticuerpos Antifosfolípidos XIII Congreso Argentino de Hemostasia y Trombosis, organizado por el GRUPO CAHT

  • A Scazziota Laboratorio de Hemostasia, Facultad de Farmacia y Bioquímica, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires
  • Y Adamczuk Laboratorio Central, Hospital General de Agudos Dr. Enrique Tornú
  • E Annetta Laboratorio de Hemostasia y Trombosis, Servicio de Hematología y Oncología, Hospital de Pediatría Prof. Dr. JP Garrahan
  • ML Bertolaccini King's College London | KCL · Academic Department of Vascular Surgery
  • AN Blanco División Hemostasia, Depto. de Hemostasia y Trombosis, IIHEMA-Academia Nacional de Medicina
  • C Duboscq Servicio Hematología y Hemoterapia, Hospital Británico
  • G Mainetti Laboratorio Central, Hospital Juan A Fernández, CABA
  • M Martinuzzo Laboratorio Central, Hospital Italiano de Buenos Aires, Instituto Universitario del Hospital Italiano
  • L Remotti División Hemostasia, Depto. de Hemostasia y Trombosis, IIHEMA-Academia Nacional de Medicina
  • E Rossi Sección Hemostasia, Laboratorio de Salud Pública, Sistema Provincial de Salud, Tucumán
Palabras clave: síndrome antifosfolípido, diagnóstico de anticoagulante lúpico, anticuerpos antifosfolípidos en fase sólida

Resumen

La presente ficha técnica constituye el material abordado en el Taller de Laboratorio de Anticuerpos Antifosfolípidos durante el XIII Congreso Argentino de Hemostasia y Trombosis llevado a cabo en la Ciudad Autónoma de Buenos Aires el 27 de septiembre de 2018.

De acuerdo con el propósito de este taller, en la siguiente ficha técnica se tratarán temas importantes para tener en cuenta en las determinaciones de laboratorio, que son herramientas indispensables para el diagnóstico del síndrome antifosfolípido.

Referencias bibliográficas

1. Cervera R, Piette JC, Font J y col. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46:1019-1027.
2. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 2013; 65:1869-1873.
3. Miyakis S, Lockshin MD, Atsumi T y col. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295-306.
4. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995; 74:1185-90.
5. Pengo V, Tripodi A, Reber G y col. Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009; 7:1737-4.
6. Ledford-Kraemer M, Moore GW, Bottenus R y col. CLSI (Clinical and Laboratory Standards Institute). Laboratory testing for the Lupus Anticoagulant: Approved Guideline. 2014; CLSI document H60-A.
7. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012; 157:47-58.
8. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies.Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014; 12:792-5.
9. Bertolaccini ML, Amengual O, Andreol L y col. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014; 13:917-30.
10. Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018; 16:809-813.
11. Molhoek JE, de Groot PG, Urbanus RT. The Lupus Anticoagulant Paradox. Semin Thromb Hemost. 2018; 44:445-452.
12. Adcock DM, Hoefner DM, Kottke-Marchant K, Marlar RA, Szamosi MA, Waruneck DJ. Collection, transport and processing of blood specimens for testing plasma-based coagulation assays and molecular Hemostasis assays. Approved Guideline. Fifth Edition, 2008. H21-A5 Document.
13. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014; 40:163-71.
14. Moore GW, Smith MP, Savidge GF. The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagul Fibrinolysis. 2003; 14:307-312.
15. Gardiner C, MacKie IJ, Malia RG y col. The importance of locally derived reference ranges and standardized calculation of dilute Russell’s viper venom time results in screening for lupus anticoagulant. Br J Haematol. 2000; 111:1230-5.
16. Tripodi A, Chantarangkul V, Cini M y col. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study. J Thromb Haemost. 2017; 15:1180-1190.
17. Kershaw G and Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin. Semin Thromb Hemost. 2013; 39:283-290.
18. Tripodi A and Chantarangkul. Lupus anicoagulant testing: activated partial thromboplastin (APTT} and Silica Clotting Time (SCT}. Hemostasis and Thrombosis, Methods and Protocols in Molecular Biology. 2017: 15:177-183.
19. Moore GW. Reference interval mean clotting times should not be used to calculate lupus anticoagulant mixing test ratios unless they match the normal pooled plasma clotting time. Thromb Res. 2017 Nov;159:16-18.
20. Duboscq C, Ceresetto J, Bullorsky E y col. Diferencias en los resultados de la detección del inhibidor lúpico según el algoritmo diagnóstico utilizado. Hematología. 2017: 281-288.
21. Martinuzzo ME, Cerrato GS, Varela M, Adamczuk YP, Forastiero RR. New guidelines for lupus anticoagulant: sensitivity and specificity of cut- off values calculated with plasmas from healthy controls in mixing and confirmatory tests. Int J Lab Hemato.l 2012; 34: 208-213.
22. Wayne P. A User Verification of Precision and Estimation of Bias; Approved Guideline. CLSI document EP15 – A3. Clinical and Laboratory Standards Institute; September 2014.
23. CLSI EP9-A2 -. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline Second Edition 2013.
24. CLSI EP 28-A3c: Defining, establishing and verifying Reference Intervals in the Clinical laboratory; Approved Guideline – Third Edition. October 2010.
25. Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol. 2014; 36:364-373.
26. Martinuzzo ME, Barrera LH, D´Adamo MA, Otaso JC, Gimenez MI, Oyhamburu J. Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2014, 36:144-150.
27. Antovic A, Norberg EM, Berndtsson M y col. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb Haemost. 2017; 117: 1700-1704.
28. Hoxha A, Banzato A, Ruffatti A y col. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev. 2017; 16:173-178.
29. Exner T, Michalopoulos N, Pearce J y col. Simple method for removing DOACs from plasma samples. Thromb Res. 2018; 163:117-122.
30. Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun. 2000; 15:179-183.
31. Rampersad AG, Boylan B, Miller CH y col. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients. Haemophilia. 2018; 24:807-814.
32. Schouwers SM, Delanghe JR, Devreese KM. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res. 2010; 125:102-104.
33. Remotti L, Grosso SH, Ingratti MF y col. Inhibidor lúpico en pacientes sin complicaciones trombóticas u obstétricas. Hematología. 2016; 20:174-181.
34. Blanco AN, Lazzari MA. Simultaneous occurrence of lupus anticoagulant and FVIII inhibitors in haemophilia. Am J Hematol. 1998; 58:248.
35. Forastiero R. Diagnóstico de laboratorio de anticuerpos antifosfolípidos/2016 Acta Bioquim Latinoam. 2016; 50:255-63.
36. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018; 378:2010-21.
37. Forastiero R. Desafíos en la interpretación del perfil de los anticuerpos antifosfolípidos. Hematología. 2018; 22:68-72.
Publicado
2019-01-21
Sección
Laboratorio en Hematología